AgomAb Therapeutics NV - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AGMB Nasdaq 2836 www.agomab.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AgomAb Therapeutics NV

Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook - Aug 6th, 2026 2:01 pm
Is AgomAB Therapeutics NV (AGMB) Stock a Biotech Opportunity With Targeted Tissue Therapy Potential? - Jul 2nd, 2026 2:06 pm
Agomab Therapeutics Shares NOV-ERA Phase 2b Study Design With Ontunisertib in Fibrostenosing Crohn's Disease - Jun 23rd, 2026 3:32 pm
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease - Jun 23rd, 2026 2:05 pm
Agomab to Participate in Upcoming Conferences - May 14th, 2026 5:30 am
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook - Apr 23rd, 2026 4:14 pm
AgomAb Therapeutics (AGMB) Wins U.S. Patent for AGMB-447 - Apr 12th, 2026 12:46 pm
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis - Mar 26th, 2026 5:00 am
European Equities Traded in the US as American Depositary Receipts Higher Wednesday - Feb 18th, 2026 9:15 am
Agomab Announces Closing of Initial Public Offering - Feb 9th, 2026 2:05 pm
Agomab indicated to open at $15.50, IPO priced at $16 - Feb 7th, 2026 8:55 am
Agomab Announces Pricing of Initial Public Offering - Feb 5th, 2026 5:24 pm